Biotech Scan

Scan

Biotech Scan

Scan symbols 22
ABBVALNYAMGNBEAMBIIBBMRNBNTXCRSPDHREDITGILDILMNINCYLEGNLLYMRNANTLANVOREGNRXRXTMOVRTX
Watchlists 1
@biotech-scan
raw scan snapshot — prices as of scan date, not live 28 rows · screens, not recommendations superseded by2026-04-26-biotech-scanported fromresearch/classic/scans/_archive/2026-03-31-biotech-scan.mdscan slugbiotech-scansource typescan-archive

The biotech complex is in a broad pullback from Q1 highs — REGN and MRNA are the only names showing any structural strength, while NVO continues its historic collapse and the gene-editing basket remains in deep bear territory. Large-cap biopharma is consolidating above SMA200 support but the short-term trend is weak-down across the board.

Price Table

Symbol Price RSI vs SMA20 7D% 30D% 3M% Trend
REGN $769.79 54.1 +1.9% +2.34% -2.66% -0.15% strong-up
MRNA $50.07 48.5 -5.3% -6.37% -5.26% +69.79% strong-up
ALNY $331.20 54.9 +3.8% +4.76% +1.89% -16.71% weak-up
EDIT $2.48 58.6 +5.6% -3.88% +15.35% +20.98% weak-up
NTLA $12.81 49.3 -2.1% -9.68% -17.03% +42.49% weak-down
INCY $93.19 46.1 -0.2% +0.44% -6.85% -5.65% weak-down
ABBV $216.49 48.6 -0.6% +4.25% -7.59% -4.49% weak-down
GILD $138.20 43.6 -2.4% -0.69% -7.36% +13.23% weak-down
AMGN $351.57 42.4 -2.5% -0.23% -8.85% +8.16% weak-down
BIIB $179.67 43.2 -3.2% +1.92% -4.46% +2.09% weak-down
LLY $916.02 40.9 -3.2% -1.58% -10.02% -14.62% weak-down
VRTX $445.47 42.8 -3.3% -0.79% -8.35% -1.74% weak-down
BMRN $55.83 43.6 -2.4% +2.07% -6.55% -6.06% down
ILMN $123.53 49.4 +0.4% -3.15% -7.04% -5.82% weak-down
DHR $189.71 42.6 -0.8% -3.16% -7.71% -16.95% strong-down
TMO $489.11 46.8 +0.7% -0.56% -3.73% -15.51% down
CRSP $46.96 42.9 -5.8% -3.90% -22.73% -10.45% strong-down
BEAM $23.83 43.5 -4.7% -9.09% -16.94% -14.03% down
BNTX $88.83 41.7 -3.0% -1.86% -17.35% -6.69% strong-down
NVO $36.19 40.9 -0.5% -4.00% -0.63% -26.26% strong-down
RXRX $3.03 37.2 -8.2% -9.24% -16.53% -25.92% strong-down
LEGN $18.02 49.0 -1.0% +0.35% -2.28% -17.11% strong-down

Tier Analysis

Momentum Leaders (RSI > 50)

  • REGN (54.1): Only large-cap with a strong-up trend and golden cross. +1.9% above SMA20, holding above all MAs. The one name in this basket that's working right now.
  • ALNY (54.9): RNAi play with weak-up trend, bouncing +4.8% this week. Off -33% from 52wk high — still in repair mode structurally, but near-term momentum turning.
  • EDIT (58.6): Penny-range gene editor, +15% in 30D and +21% in 3M. Speculative but showing relative strength vs peers. Death cross limits conviction.
  • MRNA (48.5): +69.8% in 3M is the headline — massive mRNA revival on pipeline news. Strong-up trend and golden cross despite recent -6.4% week. The big Q1 biotech winner.

Consolidating / Neutral (RSI 40-50)

  • ABBV (48.6): Resilient vs peers at only -7.6% in 30D. Golden cross, still above SMA200 (+1.2%). Best risk/reward in large-cap biopharma given strong 5Y alpha.
  • GILD (43.6): +12.8% above SMA200, golden cross — structural uptrend intact. 30D weakness is a pullback, not a breakdown. Antiviral pipeline underappreciated.
  • AMGN (42.4): +11.6% above SMA200, golden cross. -8.85% in 30D, consolidating below SMA20/50. Holding structure.
  • BIIB (43.2): +13.2% above SMA200, golden cross. ADC/neuroscience pipeline optionality. Modest pullback in an uptrend.
  • LLY (40.9): The GLP-1 king is at -14.6% in 3M and -19.2% from 52wk high. Still above SMA200 (+2.4%) — this is a pullback in a monster uptrend. Key level here.
  • VRTX (42.8): CF monopoly + pain pipeline. -8.4% in 30D but golden cross and +1.6% above SMA200. Holding support.
  • NTLA (49.3): +42.5% in 3M off the lows, then -17% in 30D gives back a chunk. Volatile gene-editing speculative play.
  • INCY (46.1): +3% above SMA200, golden cross. Grinding sideways, no breakout catalyst visible.
  • ILMN (49.4): Sequencing infrastructure play. +8% above SMA200, golden cross. -7% in 30D but shallow pullback.
  • TMO (46.8): Life science tools leader. -5.3% below SMA200, -7.1% below SMA50. In a weak downtrend despite quality franchise.

Oversold / Broken (RSI < 40)

  • DHR (42.6): Strong-down, death cross, -9.3% below SMA200. Lab equipment cycle deteriorating.
  • CRSP (42.9): Strong-down, death cross, -22.7% in 30D. Gene editing sector under pressure — commercial ramp slower than hoped.
  • BEAM (43.5): -16.9% in 30D, -34.6% from 52wk high. Base-editing story not gaining institutional traction.
  • BNTX (41.7): -17.4% in 30D, strong-down, death cross. mRNA competitor in structural decline vs MRNA's revival.
  • NVO (40.9): -55.6% from 52wk high. GLP-1 pioneer facing U.S. pricing/competition fears. Strong-down, death cross — don't catch this knife.
  • RXRX (37.2): -57.7% from 52wk high, -25.9% in 3M. AI drug discovery narrative unwinding. Avoid.
  • LEGN (49.0): -60.2% from 52wk high, -37.2% below SMA200. Cell therapy facing reimbursement headwinds.

Entry Zones

Stock Entry Range Thesis
LLY $895–$920 GLP-1 structural growth intact. Pulling back to SMA200 ($894). Buy the dip in the decade's best pharma story.
REGN $740–$770 Only large-cap biotech in strong-up. Golden cross, above all MAs. Pullback to SMA20 is the entry.
ABBV $210–$217 Best risk/reward in large-cap biopharma. Golden cross, 5Y alpha +74%.
GILD $132–$140 Antiviral + oncology pipeline undervalued. +12.8% above SMA200, golden cross.
MRNA $46–$52 +69.8% in 3M — mRNA revival. Strong-up but recent flush creates entry.
ALNY $315–$330 RNAi momentum building. Approaching SMA50 support ($330).

Action Matrix

Top Buys / Add

  1. LLY — Structural GLP-1 winner pulling back to SMA200 support. -19% from high is the entry, not the exit.
  2. REGN — Only large-cap with clean strong-up structure. Relative strength in a weak tape.
  3. ABBV — Best large-cap risk/reward. Golden cross, strong 5Y track record, modest pullback.
  4. MRNA — Quarter's biggest biotech winner (+69.8% in 3M). Strong-up, golden cross — recent flush is a shakeout.
  5. GILD — Antiviral/oncology pipeline undervalued, clean SMA200 cushion.

Top Sells / Avoid

  1. NVO — -55.6% from peak, strong-down, death cross. No floor visible.
  2. RXRX — -57.7% from 52wk high. AI drug discovery narrative broken. Exit.
  3. LEGN — -60.2% from 52wk high, -37.2% below SMA200. Cell therapy headwinds structural.
  4. CRSP/BEAM — Gene editing commercial timelines pushed out. Structural distribution.
  5. BNTX — mRNA platform losing to MRNA while own pipeline lacks near-term catalyst.

Key Observations

  • The sector is bifurcating: MRNA +69.8% in 3M vs NVO -26.3% in 3M. mRNA revival vs GLP-1 derating.
  • Large-cap biopharma is a buy-the-dip tape: ABBV, GILD, AMGN, BIIB all above SMA200 with golden crosses — the 30D weakness is a pullback not a breakdown.
  • LLY testing SMA200 is the most important level in biotech right now — if it holds, the entire sector likely stabilizes. If it breaks, valuation compression could accelerate across the group.
  • Gene editing (CRSP, BEAM, EDIT, NTLA) remains broken — commercial milestones aren't converting to institutional buying.
  • NVO's collapse (-55.6% from peak) is a sector-wide signal — U.S. pricing power fears on GLP-1s are real and spreading to the whole obesity/metabolic franchise thesis.

Data: 2026-03-31 pre-computed summaries.

10 events
DateTypeEvent
Mar 26 ScanBiotech Scan Mar 20 ScanBiotech Scan Mar 24 ScanBiotech Scan Mar 13 ScanBiotech Scan Mar 12 ScanBiotech Scan Mar 11 ScanBiotech Scan Mar 10 ScanBiotech Scan Apr 3 ScanBiotech Scan Apr 26 ScanBiotech Scan Apr 28 ScanBiotech Scan

No direct external sources are attached to this read.